Short radiation plus drugs for MSS rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a shorter course of radiation therapy followed by a combination of chemotherapy, immunotherapy, and a pain-relief medication, compared to the standard approach. It is for people with a certain type of rectal cancer that has not spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rectal cancer that has not spread to other parts of your body.
- Your tumor is located within 10 cm of your anal opening.
- Your cancer is a type called 'MSS' or 'pMMR' (a specific genetic feature).
- You are between 18 and 75 years old.
- You have not had any prior chemotherapy or immunotherapy.
- You are generally healthy and able to do daily activities without much help.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of treatments before surgery for locally advanced rectal cancer. You would receive short-course radiation, then an immunotherapy drug (camrelizumab) plus a PARP inhibitor (fluzoparib) and chemotherapy, to shrink the tumor and make surgery more successful.
This trial tests a combination of focused radiation therapy given quickly, along with chemotherapy, targeted drugs, and immunotherapy before surgery for locally advanced rectal cancer. The goal is to shrink the tumor and improve survival chances by treating the cancer aggressively before an operation.
This trial compares a new treatment approach—short-course radiation followed by an immunotherapy drug (PD-1 inhibitor) and chemotherapy (FOLFOX)—to the standard long-course chemoradiation for people with a specific type of advanced rectal cancer that is pMMR/MSS. The goal is to see if the shorter treatment works as well or better.
This study compares two different radiation therapy schedules for rectal cancer that hasn't spread to distant sites. Researchers want to see if a shorter treatment plan works as well as a longer one, potentially reducing side effects and treatment time.
This trial tests a combination of short-course radiation, an immunotherapy drug (adebrelimab), and chemotherapy (CAPEOX) before surgery to help preserve the rectum in people with MSS/pMMR ultra-low rectal cancer. The goal is to shrink the tumor enough to avoid removing the rectum.
This trial tests a treatment plan that uses a short course of radiation to the lymph nodes-sparing area, followed by chemotherapy and an immunotherapy drug (PD-1 inhibitor) for people with a specific type of mid or low rectal cancer (pMMR/MSS). The goal is to see if this approach can shrink the tumor and improve outcomes without needing extensive surgery.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.